Bio-Rad Laboratories Company Profile (NYSE:BIO)

About Bio-Rad Laboratories (NYSE:BIO)

Bio-Rad Laboratories logoBio-Rad Laboratories, Inc. (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. The Life Science segment develops, manufactures, sells and services reagents, apparatus and instruments used for biological research. The Clinical Diagnostics segment develops, manufactures, sells and services automated test systems, informatics systems, test kits and specialized quality controls for the healthcare market. As of December 31, 2016, Bio-Rad sold more than 8,000 products and services to a client base, including scientific research, healthcare, education and government customers around the world.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Medical Equipment, Supplies & Distribution
  • Sub-Industry: Life Sciences Tools & Services
  • Symbol: NYSE:BIO
  • CUSIP: 09057220
  • Web: www.bio-rad.com
Capitalization:
  • Market Cap: $6.48873 billion
  • Outstanding Shares: 29,637,000
Average Prices:
  • 50 Day Moving Avg: $222.88
  • 200 Day Moving Avg: $221.62
  • 52 Week Range: $154.89 - $242.79
P/E:
  • Trailing P/E Ratio: 431.25
  • Foreward P/E Ratio: 50.39
  • P/E Growth: 5.42
Sales & Book Value:
  • Annual Revenue: $2.08 billion
  • Price / Sales: 3.11
  • Book Value: $94.90 per share
  • Price / Book: 2.30
Profitability:
  • EBITDA: $233.59 million
  • Net Margins: 0.73%
  • Return on Equity: 3.15%
  • Return on Assets: 2.13%
Debt:
  • Debt-to-Equity Ratio: 0.15%
  • Current Ratio: 4.01%
  • Quick Ratio: 2.74%
Misc:
  • Average Volume: 162,269 shs.
  • Beta: 0.91
  • Short Ratio: 4.52
 

Frequently Asked Questions for Bio-Rad Laboratories (NYSE:BIO)

What is Bio-Rad Laboratories' stock symbol?

Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."

How were Bio-Rad Laboratories' earnings last quarter?

Bio-Rad Laboratories, Inc. (NYSE:BIO) issued its earnings results on Thursday, February, 23rd. The company reported ($0.70) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.03 by $1.73. The business had revenue of $571.45 million for the quarter, compared to the consensus estimate of $574.40 million. Bio-Rad Laboratories had a net margin of 0.73% and a return on equity of 3.15%. The company's revenue was up .1% compared to the same quarter last year. During the same period in the previous year, the firm earned $1.68 EPS. View Bio-Rad Laboratories' Earnings History.

When will Bio-Rad Laboratories make its next earnings announcement?

Bio-Rad Laboratories is scheduled to release their next quarterly earnings announcement on Thursday, November, 2nd 2017. View Earnings Estimates for Bio-Rad Laboratories.

Where is Bio-Rad Laboratories' stock going? Where will Bio-Rad Laboratories' stock price be in 2017?

3 analysts have issued 12 month target prices for Bio-Rad Laboratories' shares. Their predictions range from $250.00 to $275.00. On average, they anticipate Bio-Rad Laboratories' stock price to reach $260.00 in the next year. View Analyst Ratings for Bio-Rad Laboratories.

What are analysts saying about Bio-Rad Laboratories stock?

Here are some recent quotes from research analysts about Bio-Rad Laboratories stock:

  • 1. According to Zacks Investment Research, "Bio-Rad Laboratories, Inc., together with its subsidiaries, engages in the manufacture and supply of products and systems for the life science research, healthcare, analytical chemistry, and other markets worldwide. The company's products are used to separate complex chemical and biological materials, and to identify, analyze, and purify their components. It operates in two segments, Life Science and Clinical Diagnostics. The Life Science segment offers electrophoresis, image analysis, molecular detection, chromatography, gene transfer, sample preparation, and amplification products and services. The Clinical Diagnostics segment provides control, autoimmune, diabetes, and blood virus testing products. Bio-Rad is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. The company is headquartered in Hercules, California. " (10/12/2017)
  • 2. Jefferies Group LLC analysts commented, "Time to forget everything you thought you knew about BIO -- as two separate updates y'day included several "firsts" that add conviction to our bullish thesis: 1) 2020 rev & margin goals; 2) capital allocation plan opens the door for buybacks; 3) board shuffle / quality upgrade. Bottom line: the pathway to $300+ in 2-3 yrs just got a lot clearer & BIO's new shareholder-friendly behavior eliminates the rationale for a structural valuation discount, in our view." (3/14/2017)

Who are some of Bio-Rad Laboratories' key competitors?

Who are Bio-Rad Laboratories' key executives?

Bio-Rad Laboratories' management team includes the folowing people:

  • Norman D. Schwartz, Chairman of the Board, President, Chief Executive Officer
  • Christine A. Tsingos, Chief Financial Officer, Executive Vice President
  • John P. Goetz, Chief Operating Officer, Executive Vice President
  • Timothy Scott Ernst, Executive Vice President, General Counsel and Secretary
  • Michael Crowley, Executive Vice President, Global Commercial Operations
  • Shannon Hall, Executive Vice President, President, Life Science Group
  • John Hertia, Executive Vice President, President, Clinical Diagnostics Group
  • Giovanni Magni, Executive Vice President, Chief Strategy Officer
  • Ronald W. Hutton, Vice President, Treasurer
  • Alice N. Schwartz, Director

How do I buy Bio-Rad Laboratories stock?

Shares of Bio-Rad Laboratories can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Bio-Rad Laboratories' stock price today?

One share of Bio-Rad Laboratories stock can currently be purchased for approximately $218.21.


MarketBeat Community Rating for Bio-Rad Laboratories (NYSE BIO)
Community Ranking:  2.7 out of 5 (star star)
Outperform Votes:  149 (Vote Outperform)
Underperform Votes:  124 (Vote Underperform)
Total Votes:  273
MarketBeat's community ratings are surveys of what our community members think about Bio-Rad Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Bio-Rad Laboratories (NYSE:BIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $260.00 (19.15% upside)
Consensus Price Target History for Bio-Rad Laboratories (NYSE:BIO)
Price Target History for Bio-Rad Laboratories (NYSE:BIO)
Analysts' Ratings History for Bio-Rad Laboratories (NYSE:BIO)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
9/18/2017Deutsche Bank AGReiterated RatingBuy$255.00LowView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingBuy$275.00LowView Rating Details
7/13/2017Wells Fargo & CompanyInitiated CoverageOutperform -> Outperform$250.00HighView Rating Details
10/12/2016CL KingInitiated CoverageBuy$180.00N/AView Rating Details
11/4/2015Leerink SwannBoost Price Target$143.00 -> $149.00N/AView Rating Details
(Data available from 10/19/2015 forward)

Earnings

Earnings History for Bio-Rad Laboratories (NYSE:BIO)
Earnings by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Earnings History by Quarter for Bio-Rad Laboratories (NYSE BIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
10/30/2017$0.54N/AView Earnings Details
5/4/2017Q1 2017$0.27$0.41$477.76 million$500.05 millionViewListenView Earnings Details
2/23/2017Q416$1.03($0.70)$574.40 million$571.45 millionViewN/AView Earnings Details
11/1/2016Q316$0.51$0.62$480.60 million$508.75 millionViewN/AView Earnings Details
8/3/2016Q2$1.13$0.61$497.80 million$516.80 millionViewN/AView Earnings Details
5/5/2016Q1$0.60$0.42$463.90 million$471.20 millionViewN/AView Earnings Details
2/25/2016Q415$1.27$1.68$570.80 million$570.56 millionViewListenView Earnings Details
11/3/2015Q315$0.54$0.59$495.55 million$469.96 millionViewN/AView Earnings Details
8/6/2015Q215$0.78$0.97$494.85 million$506.10 millionViewN/AView Earnings Details
5/5/2015Q115$0.33$0.61$474.60 million$472.80 millionViewN/AView Earnings Details
2/26/2015Q414$1.18$1.34$593.41 million$598.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.86$0.39$525.40 million$530.64 millionViewN/AView Earnings Details
8/5/2014Q214$0.95$1.09$537.58 million$536.80 millionViewN/AView Earnings Details
5/6/2014Q114$0.80$0.23$515.00 million$509.30 millionViewN/AView Earnings Details
2/27/2014Q413$1.42$1.04$586.67 million$602.60 millionViewListenView Earnings Details
11/7/2013Q313$0.91($0.25)$529.02 million$505.10 millionViewListenView Earnings Details
8/6/2013Q2 2013$1.25$1.20$532.60 million$525.30 millionViewListenView Earnings Details
5/7/2013Q1 2013$1.03$0.68$506.34 million$499.70 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.33$1.65$558.68 million$573.80 millionViewN/AView Earnings Details
11/6/2012Q312$1.14$1.48$507.79 million$498.70 millionViewN/AView Earnings Details
8/7/2012$1.19$1.69ViewN/AView Earnings Details
5/1/2012$1.02$1.09ViewN/AView Earnings Details
2/23/2012$1.67$2.08ViewN/AView Earnings Details
11/1/2011$1.53$1.61ViewN/AView Earnings Details
8/2/2011$1.47$1.41ViewN/AView Earnings Details
5/3/2011$1.32$1.16ViewN/AView Earnings Details
2/24/2011$1.35$2.41ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Bio-Rad Laboratories (NYSE:BIO)
2017 EPS Consensus Estimate: $3.22
2018 EPS Consensus Estimate: $4.76
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.41$0.41$0.41
Q2 20171$0.81$0.81$0.81
Q3 20171$0.26$0.26$0.26
Q4 20171$1.74$1.74$1.74
Q1 20181$1.04$1.04$1.04
Q2 20181$1.33$1.33$1.33
Q3 20181$1.05$1.05$1.05
Q4 20181$1.34$1.34$1.34
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Bio-Rad Laboratories (NYSE:BIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Bio-Rad Laboratories (NYSE:BIO)
Insider Ownership Percentage: 28.29%
Institutional Ownership Percentage: 62.84%
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Institutional Ownership by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Insider Trades by Quarter for Bio-Rad Laboratories (NYSE:BIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/11/2017Michael CrowleyEVPSell700$215.91$151,137.00View SEC Filing  
3/7/2017Michael CrowleyEVPSell300$196.13$58,839.00View SEC Filing  
11/9/2016James R. StarkVPSell1,299$171.42$222,674.58View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Bio-Rad Laboratories (NYSE:BIO)
Latest Headlines for Bio-Rad Laboratories (NYSE:BIO)
Source:
DateHeadline
finance.yahoo.com logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : October 18, 2017
finance.yahoo.com - October 18 at 5:48 PM
americanbankingnews.com logoZacks: Brokerages Expect Bio-Rad Laboratories, Inc. (BIO) Will Post Quarterly Sales of $521.39 Million
www.americanbankingnews.com - October 17 at 8:12 AM
marketwatch.com logoGlobal Next-Generation Multi-purpose Biosensors Market 2017-2027
www.marketwatch.com - October 16 at 10:20 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Expected to Post Earnings of $0.43 Per Share
www.americanbankingnews.com - October 15 at 10:16 AM
finance.yahoo.com logoBio-Rad to Report Third-Quarter 2017 Financial Results Thursday, November 2, 2017
finance.yahoo.com - October 13 at 10:13 PM
finance.yahoo.com logoETFs with exposure to Bio-Rad Laboratories, Inc. : October 13, 2017
finance.yahoo.com - October 13 at 5:12 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Downgraded by Zacks Investment Research to Sell
www.americanbankingnews.com - October 12 at 5:46 PM
bizjournals.com logoEnteric Disease Testing Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2017 - 2025
www.bizjournals.com - October 12 at 5:21 PM
americanbankingnews.com logoQ3 2017 EPS Estimates for Bio-Rad Laboratories, Inc. (BIO) Cut by Analyst
www.americanbankingnews.com - October 11 at 7:36 AM
prnewswire.com logoGlobal MicroRNA Research Tools, Diagnostics and Therapeutics Markets 2017 ...
www.prnewswire.com - October 10 at 5:51 PM
americanbankingnews.com logoJefferies Group Comments on Bio-Rad Laboratories, Inc.'s Q4 2017 Earnings (BIO)
www.americanbankingnews.com - October 10 at 8:54 AM
marketwatch.com logoHuman Identification Market to Garner US$ 1,000 Mn by 2022 - Future Market Insights
www.marketwatch.com - October 5 at 2:44 PM
investorplace.com logoAnalysts Affirm Bio Rad Laboratories (BIO) Buy Rating
investorplace.com - October 5 at 12:57 PM
bizjournals.com logoMedical Laboratory Testing Services Market, 2022 - Cardiac, Molecular Diagnostic and Genomic
www.bizjournals.com - October 4 at 1:14 PM
finance.yahoo.com logoSenior Leadership of ARM, Verizon, Blizzard Entertainment, Peregrine Semiconductor, Extel Technologies and Bio-Rad Laboratories join EvoNexus Board of Directors
finance.yahoo.com - October 2 at 12:13 PM
finance.yahoo.com logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : September 29, 2017
finance.yahoo.com - October 2 at 12:13 PM
americanbankingnews.com logo$529.49 Million in Sales Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - September 28 at 5:12 AM
prnewswire.com logoLiquid Biopsy Market to Grow at a CAGR of 23.4% by 2022 - PR Newswire (press release)
www.prnewswire.com - September 27 at 7:36 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Expected to Announce Earnings of $0.49 Per Share
www.americanbankingnews.com - September 26 at 6:20 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Given Consensus Rating of "Buy" by Analysts
www.americanbankingnews.com - September 26 at 3:02 AM
finance.yahoo.com logoBio-Rad Laboratories, Inc. :BIO-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
finance.yahoo.com - September 21 at 4:19 PM
finance.yahoo.com logoETFs with exposure to Bio-Rad Laboratories, Inc. : September 20, 2017
finance.yahoo.com - September 20 at 2:42 AM
prnewswire.com logoGLOBAL WESTERN BLOTTING MARKET FORECAST 2017-2025
www.prnewswire.com - September 19 at 4:31 PM
globenewswire.com logoGlobal Medical Laboratory Testing Services Market 2014-2022
globenewswire.com - September 19 at 4:31 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Receives Buy Rating from Deutsche Bank AG
www.americanbankingnews.com - September 18 at 5:45 PM
globenewswire.com logoGlobal Clinical Laboratory, Cardiac, Molecular Diagnostics and Genomic Testing Services Strategies & Trends Report 2017
globenewswire.com - September 18 at 4:57 PM
finance.yahoo.com logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bullish Manner : BIO-US : September 18, 2017
finance.yahoo.com - September 18 at 4:57 PM
globenewswire.com logoProtein Expression Market to Reach $3 billion by 2023: P&S Market Research
globenewswire.com - September 14 at 5:14 PM
bizjournals.com logoEnteric Disease Testing Market Driven by Growing Prevalence of Bacterial & Parasitic Diseases, Says TMR
www.bizjournals.com - September 5 at 11:14 PM
bizjournals.com logoSingle Cell Analysis Market to Reach US$6.5 Billion by 2025: Rising Government Support, Growing Medical Tourism Vital for Steady Growth
www.bizjournals.com - September 4 at 9:55 PM
reuters.com logoBRIEF-U.S. ITC to probe certain 10X Genomics devices after Bio-Rad complaint
www.reuters.com - September 2 at 4:11 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (BIO) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - September 1 at 2:44 AM
prnewswire.com logoCell Sorting Market by Technology, Product, Application, End User - Forecasts to 2021
www.prnewswire.com - August 30 at 10:52 PM
prnewswire.com logoLegionella Testing Market Driven by Rising Investment in Medical Research, Finds TMR
www.prnewswire.com - August 30 at 2:53 AM
finance.yahoo.com logoCorporate News Blog - LabCorp's Acquisition of Chiltern Clears Antitrust Review by FTC
finance.yahoo.com - August 28 at 4:33 PM
finance.yahoo.com logoCorporate News Blog - LabCorp's Acquisition of Chiltern Clears Antitrust Review by FTC
finance.yahoo.com - August 28 at 4:33 PM
zacks.com logoIllumina Teams Up With Telegraph Hill to Form Verogen
www.zacks.com - August 25 at 6:19 PM
bizjournals.com logoBlood Transfusion Diagnostics Market to Reach US$6.0 Billion by 2025: Automated Procedures Augur Well for Future, Notes TMR
www.bizjournals.com - August 22 at 5:13 PM
americanbankingnews.com logo$0.49 EPS Expected for Bio-Rad Laboratories, Inc. (BIO) This Quarter
www.americanbankingnews.com - August 20 at 10:38 AM
finance.yahoo.com logoBio-Rad Laboratories, Inc. – Value Analysis (NYSE:BIO) : August 18, 2017
finance.yahoo.com - August 18 at 9:38 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) EVP Michael Crowley Sells 700 Shares
www.americanbankingnews.com - August 11 at 10:36 PM
finance.yahoo.com logoSee what the IHS Markit Score report has to say about Bio Rad Laboratories Inc.
finance.yahoo.com - August 10 at 2:52 AM
finance.yahoo.com logoBio-Rad Laboratories, Inc. breached its 50 day moving average in a Bearish Manner : BIO-US : August 7, 2017
finance.yahoo.com - August 7 at 5:04 PM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - August 7 at 8:26 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. Forecasted to Post Q3 2017 Earnings of $0.39 Per Share (NYSE:BIO)
www.americanbankingnews.com - August 7 at 8:08 AM
americanbankingnews.com logoBio-Rad Laboratories, Inc. (NYSE:BIO) Rating Lowered to C+ at TheStreet
www.americanbankingnews.com - August 5 at 9:36 AM
finance.yahoo.com logoEdited Transcript of BIO earnings conference call or presentation 3-Aug-17 9:00pm GMT
finance.yahoo.com - August 4 at 4:50 PM
finance.yahoo.com logoBio-Rad misses 2Q profit forecasts
finance.yahoo.com - August 4 at 4:50 PM
finance.yahoo.com logoBio-Rad posts 2Q profit
finance.yahoo.com - August 4 at 4:50 PM
finance.yahoo.com logoInvestor Network: Bio-Rad Laboratories, Inc. to Host Earnings Call
finance.yahoo.com - August 3 at 6:01 PM

Social

Chart

Bio-Rad Laboratories (BIO) Chart for Thursday, October, 19, 2017

This page was last updated on 10/19/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.